Gene therapy for neurologic disease

Archives of Neurology

Volumn 50, Issue 11, 1993, Pages 1252-1268

  Suhr, Steven T ^a   Gage, Fred H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ALZHEIMER DISEASE; BRAIN INJURY; BRAIN TUMOR; ENHANCER REGION; GENE THERAPY; GENE TRANSFER; HUMAN; LESCH NYHAN SYNDROME; LYSOSOME STORAGE DISEASE; MOLECULAR GENETICS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ADENOVIRIDAE; ALZHEIMER DISEASE; BRAIN NEOPLASMS; CELL DIVISION; DNA; ENHANCER ELEMENTS (GENETICS); GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC MARKERS; GENETIC VECTORS; HETEROZYGOTE; HUMAN; METABOLISM, INBORN ERRORS; NERVOUS SYSTEM DISEASES; NEURONS; PARKINSON DISEASE; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; TEMPLATES, GENETIC;

EID: 0027525494     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1993.00540110122012     Document Type: Article

References (164)

1. Gage FH, Wolff JA, Rosenberg MB, et al. Grafting genetically modified cells to the brain: possibilities for the future. Neuroscience. 1987;23:795-807.
2. Friedmann T. Progress toward human gene therapy. Science. 1989;244:1275-1281.
3. Verma IM. Gene therapy. Sci Am. 1990;263:68-72, 81-84.
4. Miller AD. Human gene therapy comes of age. Nature. 1992;357:455-460.
5. Anderson WF. Human gene therapy. Science. 1992;256:808-813.
6. Mulligan RC. The basic science of gene therapy. Science. 1993;260:926-932.
7. Soriano P, Friedrich G, Lawinger P. Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells. J Virol. 1991;65: 2314-2319.
8. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 1992;20:1293-1299.
9. Boris-Lawrie KA, Temin HM. Recent advances in retrovirus vector technology. Curr Op Genet Dev. 1993;3:102-109.
10. Pfarr DS, Rieser LA, Woychik RP, Rottman FM, Rosenberg M, Reff ME. Differential effects of polyadenylation regions on gene expression in mammalian cells. DNA. 1986;5:115-122.
11. Wolff JA, Fisher LJ, Xu L, et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA. 1989;86:9011-9014.
12. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron. 1991;6:371-380.
13. Fisher LJ, Schinstine M, Salvaterra P, Dekker AJ, Thai L, Gage FH. In vivo production and release of acetylcholine from primary fibroblasts genetically modified to express choline acetyltransferase. J Neurochem. In press.
14. Miyanohara A, Johnson PA, Elam RL, et al. Direct gene transfer to the liver with herpes simplex virus type 1 vectors: transient production of physiologically relevant levels of circulating factor IX. New Biol. 1992;4:238-246.
15. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA. 1991;88:1330-1334.
16. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A. 1991;88:4626-4630.
17. Donovan DM, Takemura M, O'Hara BF, Brannock MT, Uhl GR. Preproenkephalin promoter 'cassette' confers brain expression and synaptic regulation in transgenic mice. Proc Natl Acad Sci U S A. 1992;89:2345-2349.
18. Forss-Petter S, Danielson PE, Catsicas S, et al. Transgenic mice expressing B-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron. 1990;5:187-197.
19. Banerjee SA, Hoppe P, Brilliant M, Chikaraishi DM. 5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J Neurosci. 1992;12:4460-4467.
20. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A. 1992;89:10892-10895.
21. Palella TD, Hidaka Y, Silverman LJ, Levine M, Glorioso J, Kelley WN. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene. 1989;80:137-144.
22. Palella TD, Silverman LJ, Homa FL, Levine M, Kelley WN. Transfer of human HPRT gene sequences into neuronal cells by a herpes simplex virus derived vector. Adv Exp Med Biol. 19892;253A:549-554.
23. Federoff HJ, Geschwind MD, Geller Al, Kessler JA. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci U S A. 1992;89:1636-1640.
24. Yang NS. Gene transfer into mammalian somatic cells in vivo. Crit Rev Biotechnol. 1992;12:335-356.
25. Chen CA, Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques. 1988;6:632-638.
26. Andreason GL, Evans GA. Optimization of electroporation for transfection of mammalian cell lines. Anal Biochem. 1989;180:269-275.
27. Felgner PL, Gadek TR, Holm M, et al. Lipofectin: a highly efficient, lipid-mediated DNA-transfer procedure. Proc Natl Acad Sci U S A. 1987;84:7413-7417.
28. Felgner PL, Holm M. Cationic liposome-mediated transfection. Focus. 1989; 11:21-25.
29. Ray J, Gage FH. Gene transfer into established and primary fibroblast cell lines: comparison of transfection methods and promoters. Biotechniques. 1992; 13:598-603.
30. Eglitis MA. Positive selectable markers for use with mammalian cells in culture. Hum Gene Ther. 1991;2:195-201.
31. Emerman M, Temin HM. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol. 1986;6:792-800.
32. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18:3587-3596.
33. Miller AD. Retrovirus packaging cells. Hum Gene Ther. 1990;1:5-14.
34. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85:6460-6464.
35. Cepko C. Retrovirus vectors and their applications to neurobiology. Neuron. 1988;1:345-353.
36. Cunningham LA, Hansen JT, Short MP, Bohn MC. The use of genetically altered astrocytes to provide nerve growth factor to adrenal chromaffin cells grafted into the striatum. Brain Res. 1991;561:192-202.
37. Brundin P, Isacson O, Bjorklund A. Monitoring of cell viability in suspension of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. Brain Res. 1985;331:251-259.
38. Zhu SM, Kujirai K, Dollison A, Angulo J, Fahn S, Cadet JL. Implantation of genetically modified mesencephalic fetal cells into the rat striatum. Brain Res Bull. 1992;29:81-93.
39. Ray J, Peterson DA, Schinstine M, Gage FH. Proliferation, differentiation, and long-term culture of primary hippocampal neurons. Proc Natl Acad Sci U S A. 1993;90:3602-3606.
40. Kilpatrick TJ, Bartlett P. Cloning and growth of multipotential neural precursors: requirements for proliferation and differentiation. Neuron. 1993;10:255-265.
41. Horellou P, Marlier L, Privat A, et al. Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease. Prog Brain Res. 199082:23-32.
42. Espinosa de los Monteros A, Zhang M, de Vellis J. O2A progenitor cells transplanted into the neonatal rat brain develop into oligodendrocytes but not astrocytes. Proc Natl Acad Sci U S A. 1993;90:50-54.
43. Shimohama S, Rosenberg MB, Fagan AM, et al. Grafting genetically modified cells into the rat brain: characteristics of E coli beta-galactosidase as a reporter gene. Brain Res Mol Brain Res. 1989;5:271-278.
44. Uchida K, Takamatsu K, Kaneda N, et al. Synthesis of L-3,4-dihydroxyphenylalanine by tyrosine hydroxylase cDNA-transfected C6 cells: application for intracerebral grafting. J Neurochem. 1989;53:728-732.
45. Ronnett GV, Hester LD, Nye JS, Connors K, Snyder SH. Human cortical neuronal cell line: establishment from a patient with unilateral megalencephaly. Science. 1990;248:603-605.
46. Ryder EF, Snyder EY, Cepko CL. Establishment and characterization of multipotent neural cell lines using retrovirus vector-mediated oncogene transfer. J Neurobiol. 1990;21:356-375.
47. Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwieg EA, Cepko CL. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell. 1992;68:33-51.
48. Rosenberg MB, Friedmann T, Robertson RC. et al. Grafting of genetically modified cells to the damaged brain: restorative effects of NGF expression. Science. 1988;242:1575-1578.
49. Jiao S, Schultz E, Wolff JA. Intracerebral transplants of primary muscle cells: a potential 'platform' for transgene expression in the brain. Brain Res. 1992; 575:143-147.
50. Jiao S, Williams P, Berg RK, et al. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther. 1992;3:21-33.
51. Jiao S, Gurevich V, Wolff JA. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature. 1993;362:450-453.
52. Horellou P, Brundin P, Kalen P, Mallet J, Bjorklund A. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron. 1990;5:393-402.
53. Kawaja MD, Fisher LJ, Schinstine M, et al. Grafting genetically modified cells within the rat central nervous system: methodological considerations. In: Dunnett SB, Bjorklund A, eds. Neural Transplantation: A Practical Approach. New York, NY: Oxford University Press; 1992:1.
54. Gage FH, Kawaja MD, Fisher LJ. Genetically modified cells: applications for intracerebral grafting. Trends Neurosci. 1991;14:328-333.
55. Piccardo P, Maysinger D, Cuello AC. Recovery of nucleus basalis cholinergic neurons by grafting NGF secretor fibroblasts. Neuroreport. 1992;3:353-356.
56. Kawaja MD, Fagan AM, Firestein BL, Gage FH. Intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum: an assessment of graft size and ultrastructure. J Comp Neurol. 1991;307:695-706.
57. Stromberg I, Wetmore CJ, Ebendal T, Ernfors P, Persson H, Olson L. Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF. J Neurosci Res. 1990;25:405-411.
58. Tuszynski MH, Amaral DG, Gage FH. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 1990;10:3604-3614.
59. Tuszynski MH, Sang H, Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol. 1991;30:625-636.
60. Kolberg R. Animal models point the way to human clinical trials. Science. 1992;256:772-773.
61. Breakefield XO, DeLuca NA. Herpes simplex virus for gene delivery to neurons. New Biol. 1991;3:203-218.
62. Gomez-Foix AM, Coats WS, Baque S, et al. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem. 1992;267:25129-25134.
63. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 1992;68:143-155.
64. Ugolini G, Kuypers HG, Strick PL. Transneuronal transfer of herpes virus from peripheral nerves to cortex and brainstem. Science. 1989;243:89-91.
65. Freese A, Geller A. Infection of cultured striatal neurons with a defective HSV-1 vector: implications for gene therapy. Nucleic Acids Res. 1991;19:7219-7223.
66. Johnson PA, Miyanohara A, Levine F, Cahill T, Friedmann T. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol. 1992;66: 2952-2965.
67. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell. 1982;30:295-304.
68. Geller Al, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science. 1988;241:1667-1669.
69. Geller Al. A system, using neural cell lines, to characterize HSV-1 vectors containing genes which affect neuronal physiology, or neuronal promoters. J Neurosci Methods. 1991;36:91-103.
70. Huang Q, Vonsattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Exp Neurol. 1992;115:303-316.
71. Geller Al, During MJ, Neve RL. Molecular analysis of neuronal physiology by gene transfer into neurons with herpes simplex virus vectors. Trends Neurosci. 1991;14:428-432.
72. Chiocca EA, Choi BB, Cai WZ, et al. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol. 1990;2:739-746.
73. Hidaka Y, Kelley WN, Levine M, et al. Expression of human hypoxanthine guanine phosphoribosyltransferase mRNA in brains of mice infected with a recombinant herpes simplex virus type 1. Trans Assoc Am Physicians. 1989; 102:91-100.
74. Martuza RL, Malick A, Marker JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-855.
75. Le Gal La Salle G, Robert JJ, Berrard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science. 1993;259:988-990.
76. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci US A. 1992;89:2581-2584.
77. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45:555-564.
78. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Topics Microbiol Immunol. 1992;158:99-129.
79. Muro-Cacho CA, Samulski RJ, Kaplan D. Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J Immunother. 1992; 11:231-237.
80. Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A. 1992;89:7257-7261.
81. Varmus H. Retroviruses. Science. 1988;240:1427-1435.
82. Fredericksen K, Jat PS, Valtz N, Levy D, McKay R. Immortalization of precursor cells from the mammalian CNS. Neuron. 1988;1:439-448.
83. Lendahl U, McKay RD. The use of cell lines in neurobiology. Trends Neurosci. 1990;13:132-137.
84. Cepko CL. Immortalization of neural cells via retrovirus-mediated oncogene transduction. Annu Rev Neurosci. 1989;12:47-65.
85. Correll PH, Fink JK, Brady RO, Perry LK, Karlsson S. Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoetic progenitor cells. Proc Natl Acad Sci U S A. 1989;86:8912-8916.
86. Correll PH, Colilla S, Dave HP, Karlsson S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood. 1992;80:331-336.
87. Miller AD, Jolly DJ, Friedmann T, Verma IM. A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci U S A. 1983;80:4709-4713.
88. Miller AD, Eckner RJ, Jolly DJ, Friedmann T, Verma IM. Expression of a retrovirus encoding human HPRT in mice. Science. 1984;225:630-632.
89. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-1468.
90. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques. 1991;11:474-485.
91. Jiao S, Acsadi G, Jani A, Feigner PL, Wolff JA. Persistence of plasmid DNA and expression in rat brain cells in vivo. Exp Neurol. 1992;115:400-413.
92. Klein RM, Wolf ED, Wu R, Sanford JC. High-velocity microprojectiles for delivering nucleic acids into living cells. Biotechnology. 1992;24:384-386.
93. Zelenin AV, Titomirov AV, Kolesnikov VA. Genetic transformation of mouse cultured cells with the help of high-velocity mechanical DNA injection. FEBS Lett. 1989;244:65-67.
94. Zelenin AV, Alimov AA, Titomirov AV, Kazansky AV, Gorodetsky SI, Kolesnikov VA. High-velocity mechanical DNA transfer of the chloramphenicolacetyl transferase gene into rodent liver, kidney and mammary gland cells in organ explants and in vivo. FEBS Lett. 1991;280:94-96.
95. Gage FH. Intracerebral grafting of genetically modified cells acting as biological pumps. Trends Phys Sci. 1990;11:437-439.
96. Palmer TD, Thompson AR, Miller AD. Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood. 1989;73:438-445.
97. Roman M, Axelrod JH, Dai Y, Naviaux RK, Friedmann T, Verma IM. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat Cell Mol Genet. 1992;18:247-258.
98. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesensephalic grafting in two patients with Parkinsonism induced by MPTP. N Engl J Med. 1992; 327:1556-1563.
99. Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med. 1987;316:831-834.
100. Kassirer JP, Angell M. The use of fetal tissue in research of Parkinson's disease. N Engl J Med. 1992;327:1591-1592.
101. Gage FH. Fetal implants put to the test. Nature. 1993;361:405-406.
102. Fahn S. Fetal-tissue transplants in Parkinson's disease. N Engl J Med. 1992; 327:1589-1590.
103. Garry DJ, Caplan AL, Vawter DE, Kearney W. Are there really alternatives to the use of fetal tissue from elective abortions in transplantation research? N Engl J Med. 1992;327:1592-1595.
104. Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system: a review and speculative synthesis. Brain Res Rev. 1988;13:287-324.
105. Walters AM, Clarke DJ, Bradford HF, Stern GM. The properties of cultured fetal human and rat brain tissue and its use as grafts for the relief of Parkinson's syndrome. Neurochem Res. 1992;17:893-900.
106. Tsuda M, Yuasa S, Fujino Y, et al. Retrovirus-mediated gene transfer into mouse cerebellar primary culture and its application to neural transplantation. Brain Res Bull. 1990;24:787-792.
107. Whittemore SR, Holets VR, Keane RW, Levy DJ, Mckay RD. Transplantation of a temperature-sensitive, nerve growth factor-secreting, neuroblastoma cell line into adult rats with fimbria-fornix lesions rescues cholinergic septal neurons. J Neurosci Res. 1991;28:156-170.
108. Renfranz PJ, Cunningham MG, McKay RD. Region-specific differentiation of the hippocampal stem cell line HiB5 upon implantation into the developing mammalian brain. Cell. 1991;66:713-729.
109. White LA, Whittemore SR. Immortalization of raphe neurons: an approach to neuronal function in vitro and in vivo. J Chem Neuroanat. 1992;5:327-330.
110. Gage FH, Fisher LJ, Jinnah HA, Rosenberg MB, Tuszynski MH, Friedmann T. Grafting genetically modified cells to the brain: conceptual and technical issues. Prog Brain Res. 1990;82:1-10.
111. Jiao S, Wolff JA. Long-term survival of autologous muscle grafts in rat brain. Neurosci Lett. 1992;137:207-210.
112. Kawaja MD, Gage FH. Morphological and neurochemical features of cultured primary skin fibroblasts of Fischer 344 rats following striatal implantation. J Comp Neurol. 1992;317:102-116.
113. Chen LS, Ray J, Fisher LJ, et al. Cellular replacement therapy for neurologic disorders: potential of genetically engineered cells. J Cell Biochem. 1991;45: 252-257.
114. Fisher LJ, Gage FH. Grafting in the mammalian central nervous system. Ann Rev Physiol. In press.
115. Mahanthappa NK, Gage FH, Patterson PH. Adrenal chromaffin cells as multipotential neurons for autografts. Prog Brain Res. 1990;82:33-39.
116. Ernfors P, Ebendal T, Olson L, Mouton P, Stromberg I, Persson H. A cell line producing recombinant nerve growth factor evokes growth responses in intrinsic and grafted central cholinergic neurons. Proc Natl Acad Sci U S A. 1989;86:4756-4760.
117. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-983.
118. Dunnet SB. Neural transplantation in animal models of dementia. Eur J Neu rosci. 1990;2:567-587.
119. Gage FH, Fisher LJ. Intracerebral grafting: a tool for the neurobiologist. Neuron. 1991;6:1-12.
120. Gage FH, Chen KS. Neural transplants: prospects for Alzheimer's disease. Curr Opin Neurol Neurosurg. 1992;5:94-99.
121. Dunnett SB. Transplantation of embryonic dopamine neurons: what we know from rats. J Neurol. 1991;238:65-74.
122. Phelps CH, Gage FH, Growdon JH, et al. Potential use of nerve growth factor to treat Alzheimer's disease. Neurobiol Aging. 1989;10:205-207.
123. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci. 1986;6:2155-2162.
124. Williams LR, Varon S, Peterson GM, et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A. 1986;83:9231-9235.
125. Gage FH, Tuszinski MH, Chen KS, Fagan AM, Higgins GA. Nerve growth factor function in the central nervous system. Curr Top Microbiol Immunol. 1991; 165:71-93.
126. Thanos S, Bahr M, Barde YA, Vanselow J. Survival and axonal elongation of adult rat retinal ganglion cells. Eur J Neurosci. 1989;1:19-26.
127. Hofer MM, Barde YA. Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature. 1988;331:261-262.
128. Sendtner M, Holtmann B, Kolbeck R, Thoenen H, Barde YA. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature. 1992;360:757-758.
129. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329:65-68.
130. Friden PM, Walus LR, Watson P, et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science. 1993;259:373-377.
131. Schinstine M, Kawaja MD, Gage FH. Intracerebral delivery of growth factors: potential application of genetically modified fibroblasts. Prog Growth Factor Res. 1991;3:57-66.
132. Gage FH, Rosenberg MB, Tuszynski MH, et al. Gene therapy in the CNS: intracerebral grafting of genetically modified cells. Prog Brain Res. 1990:86: 205-217.
133. Frim DM, Short MP, Rosenberg WS, Simpson J, Breakefield XO, Isacson O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. J Neurosurg. 1993;78:267-273.
134. Maysinger D, Piccardo P, Goiny M, Cuello C. Grafting of genetically modified cells: effects of acetylcholine release in vivo. Neurochem Int. 1992;21:543-548.
135. Kawaja MD, Rosenberg MB, Yoshida K, Gage FH. Somatic gene transfer of nerve growth factor promotes the survival of axotomized septal neurons and the regeneration of their axons in adult rats. J Neurosci. 1992;12:2849-2864.
136. Schinstine M, Rosenberg MB, Routledge-Ward C, Friedmann T, Gage FH. Effects of choline and quiescence on Drosophila choline acetyltransferase expression and acetylcholine production by transduced rat fibroblasts. J Neurochem. 1992;58:2019-2029.
137. Habert E, Birman S, Mallet J. High-level synthesis and fate of acetylcholine in baculovirus-infected cells: characterization and purification of recombinant rat choline acetyltransferase. J Neurochem. 1992;58:1447-1453.
138. Chen KS, Tuszynski MH, Gage FH. Role of neurotrophic factors in Alzheimer's disease. Neurobiol Aging. 1989;10:545-546.
139. Tuszynski MH. Jinnah HA, Gage FH. Delivery of neuroactive compounds to the brain: potential utility of genetically modified cells. Neurobiol Aging. 1989; 10:644-645.
140. Gage FH, Kang UJ, Fisher LJ. Intracerebral grafting in the dopaminergic system: issues and controversy. Curr Opin Neurobiol. 1991;1:414-419.
141. Horellou P, Lundberg C, Le Bourdelles B, et al. Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease. J Physiol (Paris). 1991;85:158-170.
142. Tuszynski MH, Ray J, Gage FH, Peterson DA. Cells genetically modified to secrete NGF induce dense growth of sensory fibers after transplantation to the spinal chord. Soc Neurosci Abs. 1992;18:1479.
143. Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol. 1991;3:709-715.
144. Ezzeddine ZD, Martuza RL, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991;3:608-614.
145. Barba D, Hardin J, Ray J, Gage FH. Thymidine kinase mediated killing of rat brain tumors. J Neurosurg. In press.
146. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
147. Kaleko M, Garcia JV, Miller AD. Persistent gene expression after retroviral gene transfer into liver cells in vivo. Hum Gene Ther. 1991;2:27-32.
148. Miyanohara A, Elam RL, Witztum JL, Friedmann T. Long-term transgene expression from genetically modified hepatocytes grafted to the rat liver. New Biol. 1992;4:261-267.
149. Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science. 1992;256:794-799.
150. Kohn DB, Nolta JA, Weinthal J, et al. Toward gene therapy for Gaucher disease. Hum Gene Ther. 1991;2:101-105.
151. Fink JK, Correll PH, Perry LK, Brady RO, Karlsson S. Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc Natl Acad Sci U S A. 1990;87:2334-2338.
152. Weinthal J, Nolta JA, Yu XJ, Lilley J, Uribe L, Kohn DB. Expression of human glucocerebrosidase following retroviral vector-mediated transduction of murine hematopoietic stem cells. Bone Marrow Transplant. 1991;8:403-412.
153. Ohashi T, Boggs S, Robbins P, et al. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA. 1992;89:11332-11336.
154. Nolta JA, Yu XJ, Bahner I, Kohn DB. Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow. J Clin Invest. 1992;90:342-348.
155. Wolfe JH, Sands MS, Barker JE, et al. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature. 1992; 360:749-753.
156. Caskey CT, Kruh GD. The HPRT locus. Cell. 1979;16:1-19.
157. Kelley WN, Wyngaarden JB. Clinical syndromes associated with hypoxanthine-guanine phosphoribosyltranasferase deficiency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, ed. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill International Book Co; 1983:1115-1143.
158. Jinnah HA, Gage FH, Friedmann T. Animal models of Lesch-Nyhan syndrome. Brain Res Bull. 1990;25:467-475.
159. Hooper M, Hardy K, Handyside A, Hunter S, Monk M. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature. 1987;326:292-295.
160. Kuehn MR, Bradley A, Robertson EJ, Evans MJ. A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature. 1987;326:295-298.
161. Jinnah HA, Gage FH, Friedmann T. Amphetamine-induced behavioral phenotype in a hypoxanthine-guanine phosphoribosyltransferase-deficient mouse model of Lesch-Nyhan syndrome. Behav Neurosci. 1991;105:1004-1012.
162. Willis RC, Jolly DJ, Miller AD, et al. Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-guanine phosphoribosyltransferase-deficient) lymphoblasts with a transmissible retroviral vector. J Biol Chem. 1984;259:7842-7849.
163. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62.
164. Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature. 1993;361: 726-730.